ArticleEClinicalMedicine2025
Real-world effectiveness of initial antiviral regimens in children with chronic hepatitis B: an age-stratified cohort study.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [A real-world study of clinical cure in children with HBeAg-positive chronic hepatitis B from the Guangxi region].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- [Progress in clinical research related to viral hepatitis in 2025].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- [Comparison of antiviral efficacy of nucleos(t)ide analogue monotherapy and its combination with interferon-α in children 1-6 years-old with HBeAg-positive chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interferons (IFN-α) and nucleos(t)ide analogues (NAs) are currently the primary treatment options for children with chronic hepatitis B (CHB), but the efficacy of different initial antiviral regimens in children with different ages remains unclear. Methods: This study included 483 treatment-naïve children with CHB who received initial antiviral therapy at Hunan Children's Hospital between June 2015 and November 2023. According to the initial 24-week regimens, patients were divided into (Peg) IFN-α monotherapy, NAs monotherapy, and combination therapy groups, and stratified by age of treatment initiation (1-7 years vs. ≥ 7 years). The study outcome was HBsAg loss. Propensity score matching (PSM) was used to adjust for confounding factors, and a sensitivity analysis was performed to assess the robustness of the results. Findings: Of the 483 subjects, 294 (60.87%) were male, with a median age of 5 years. Median (interquartile range) follow-up duration was 90 (53, 156) weeks. 158 (32.71%), 56 (11.59%), and 269 (55.69%) participants were assigned to (Peg) IFN-α monotherapy, NAs monotherapy, and combination therapy groups, respectively. After adjusting for other covariates, HBsAg loss rates were comparable in the (Peg) IFN-α monotherapy group and the combination treatment group in children aged 1-7 years ((Peg) IFN-α: Reference group, NAs: HR (95% CI) 0.47 (0.23-0.96), Combination: 1.31 (0.94-1.82)); while HBsAg loss rate was significantly higher in the combination treatment group compared to the other two groups in children aged ≥7 years group (NAs: 0.70 (0.23-2.19), Combination: 3.02 (1.42-6.45)). PSM and sensitivity analyses observed similar findings. Interpretation: Initial combination therapy had a significant advantage over HBsAg loss in CHB children. In children aged 1-7 years, (Peg) IFN-α monotherapy and combination therapy achieved comparable efficacy; in children aged ≥7 years, combination therapy was more advantageous. Antiviral therapy for children with CHB should be individualized according to the age at treatment initiation to optimize clinical benefit. Funding: The National Natural Science Foundation of China, grant number (82103861); The Natural Science Foundation of Hunan Province, China (2024JJ5457).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.